efficaci
novel
beiinactiv
porcin
reproduct
respiratori
syndrom
viru
prrsv
candid
vaccin
pig
develop
ribsp
republ
kazakhstan
deliv
adjuv
montanid
tm
gel
st
dkvadj
compar
commerci
kill
prrsv
vaccin
ckvadj
use
wide
swine
herd
republ
kazakhstan
clinic
paramet
bodi
temperatur
respiratori
diseas
score
virolog
immunolog
profil
elisa
viru
neutral
vn
antibodi
titer
macroscop
lung
lesion
viral
load
lung
quantit
realtim
pcr
cell
cultur
assay
assess
vaccin
genotyp
prrsv
challeng
pig
result
show
commerci
vaccin
fail
protect
pig
adequ
clinic
diseas
viremia
lung
lesion
caus
challeng
field
isol
kazakh
strain
prrsv
type
type
genotyp
contrast
clinic
protect
absenc
viremia
lung
lesion
dkvadj
vaccin
pig
associ
gener
vn
antibodi
homolog
vaccin
strain
lkz
prrsv
type
heterogen
type
prrsv
strain
challeng
pig
thu
data
indic
induct
crossprotect
vn
antibodi
dkvadj
vaccin
importantli
demonstr
inactiv
prrsv
vaccin
could
also
induc
crossprotect
respons
across
viral
genotyp
porcin
reproduct
respiratori
syndrom
prr
econom
devast
diseas
pig
caus
estim
direct
loss
greater
million
annual
us
pork
industri
chand
et
al
holtkamp
kliebenstein
caus
agent
prr
viru
prrsv
belong
famili
arterivirida
order
nidoviral
caus
respiratori
problem
pig
age
reproduct
failur
sow
includ
still
birth
mummif
birth
weak
piglet
high
prewean
mortal
kimman
et
al
rossow
et
al
genet
antigen
analys
reveal
two
distinct
prrsv
genotyp
european
type
north
american
type
mark
genet
antigen
differ
observ
type
type
prrsv
genotyp
kim
et
al
nelsen
et
al
addit
within
genotyp
genet
variat
type
type
ii
prrsv
exist
kim
et
al
zimmerman
et
al
impli
complex
prrsv
difficulti
develop
protect
vaccin
li
et
al
vaccin
viabl
strategi
practic
control
clinic
prr
diseas
transmiss
pig
two
type
prrsv
vaccin
commerci
avail
modifi
live
viru
mlv
vaccin
kill
viru
kv
vaccin
charerntantanakul
prr
mlv
vaccin
shown
provid
protect
efficaci
prrsv
infect
field
howev
provid
limit
protect
heterolog
virus
addit
prr
mlv
vaccin
intrins
risk
revers
virul
strain
kwang
et
al
though
prr
kv
vaccin
safe
use
pig
elicit
insuffici
immun
pig
lee
et
al
overal
commerci
avail
prr
kv
vaccin
induc
strong
requir
immun
respons
thu
fail
protect
pig
viremia
homolog
well
heterolog
viral
challeng
nilubol
et
al
scortti
et
al
zuckermann
et
al
interestingli
experiment
studi
show
possibl
induc
product
viru
neutral
vn
antibodi
respons
pig
immun
inactiv
prrsv
misinzo
et
al
renukaradhya
et
al
passiv
transfer
studi
demonstr
prr
vn
antibodi
respons
respons
viral
clearanc
blood
lung
reduc
transplacent
transmiss
viru
thu
play
signific
role
protect
immun
respons
prr
lopez
osorio
osorio
et
al
recent
research
effort
aim
improv
protect
immun
respons
prr
kv
focus
util
potent
vaccin
adjuv
help
reduc
viremia
lung
lesion
clinic
diseas
homolog
heterogen
prrsv
challeng
pig
sever
type
vaccin
adjuv
investig
abil
potenti
immun
respons
prr
vaccin
charerntantanakul
li
et
al
exampl
polymer
adjuv
montanid
tm
gel
devil
et
al
parker
et
al
tabynov
et
al
previou
work
laboratori
demonstr
montanid
tm
gel
potenti
immun
respons
candid
inactiv
prr
vaccin
time
efficaci
compar
commerci
vaccin
therefor
develop
binari
ethylenimin
bei
inactiv
experiment
prrsv
vaccin
contain
prrsv
strain
type
coadminist
intramuscularli
montanid
tm
gel
st
adjuv
vaccin
viru
isol
territori
republ
kazakhstan
elucid
efficaci
candid
kv
prr
vaccin
vaccin
piglet
challeng
parent
type
vaccin
strain
type
heterogen
strain
prrsv
prrsv
strain
nation
repositori
especi
danger
diseas
republ
kazakhstan
registr
number
propag
cell
use
experiment
vaccin
prepar
viru
infect
cell
cultur
supernat
fifth
passag
harvest
h
infect
centrifug
rpm
min
filter
mm
filter
viru
titer
determin
use
confluent
monolay
cell
cultur
h
tissu
cultur
plate
viral
titer
express
tcid
ml
reed
muench
inactiv
prrsv
bei
perform
describ
bahnemann
modif
azanbekova
et
al
briefli
bei
stock
solut
prepar
cycliz
naoh
h
c
store
c
viru
inactiv
incub
mm
bei
h
c
unutil
bei
neutral
incub
mm
sodium
thiosulph
c
overnight
confirm
complet
inactiv
inactiv
viru
suspens
inocul
onto
cell
cultur
cm
tissu
cultur
flask
ml
medium
cell
cultiv
week
c
time
passag
three
time
absenc
cpe
confirm
furthermor
ml
inactiv
prrsv
inject
three
pig
serum
sampl
collect
everi
week
week
assay
viremia
realtim
pcr
describ
section
confirm
viral
inactiv
viral
antigen
mix
final
concentr
ww
gel
st
polymer
adjuv
montanid
tm
seppic
franc
manual
shake
min
prrsv
vaccin
use
studi
candid
kv
vaccin
mix
polymer
adjuv
dkvadj
ribsp
gvardeiskiy
kazakhstan
batch
commerci
kv
vaccin
contain
oil
base
adjuv
ckvadj
guangdong
dahuanong
anim
health
product
co
ltd
jinan
china
batch
challeng
prrsv
strain
includ
prrsv
type
isol
lugovskoi
konniy
zavod
lkz
farm
zhambylskaya
oblast
kazakhstan
orynbayev
et
al
type
isol
privat
farm
zatobol
villag
kostanayskiy
rayon
kazakhstan
tabynov
et
al
obtain
depositori
especi
danger
infecti
diseas
ribsp
challeng
viru
strain
propag
cell
confirm
type
type
virus
ezprrsv
tm
mpx
real
time
rtpcr
use
targetspecif
reagent
kit
rapid
identif
differenti
north
american
european
prr
viral
rna
tetracor
md
usa
fifti
larg
white
breed
pig
weigh
kg
averag
monthsold
purchas
specificpathogenfre
herd
certifi
record
show
free
prrsv
porcin
parvoviru
porcin
respiratori
coronaviru
aujeszki
diseas
classic
swine
fever
viru
transmiss
gastroenter
viru
swine
influenza
viru
mycoplasma
hyopneumonia
neg
prrsv
statu
anim
confirm
serolog
use
commerci
elisa
kit
arriv
anim
facil
pig
randomli
assign
six
treatment
group
group
mockvaccin
neg
control
group
receiv
ml
final
concentr
gel
adjuv
group
vaccin
three
time
day
postfirst
vaccin
dpfv
volum
ml
dkvadj
contain
gel
adjuv
group
vaccin
twice
dpfv
ml
commerci
ckvadj
vaccin
contain
oil
adjuv
per
manufactur
recommend
viru
titer
present
dkvadj
ckvadj
vaccin
inactiv
tcid
ml
tcid
ml
respect
dpfv
neg
control
group
n
pigsgroup
group
n
pigsgroup
challeng
intranas
tcid
intramuscularli
tcid
prrsv
tabl
serum
sampl
collect
pig
dpfv
store
c
use
assay
pig
euthan
dpfv
use
mixtur
ketamin
xylazin
previous
describ
perform
necropsi
pig
hous
isol
anim
facil
research
institut
biolog
safeti
problem
scienc
committe
ministri
educ
scienc
republ
kazakhstan
ribsp
anim
free
access
filter
water
unmed
steril
feed
pig
initi
kept
acclim
period
day
start
vaccin
studi
carri
complianc
nation
intern
law
guidelin
anim
handl
anim
use
protocol
approv
committe
ethic
anim
experi
ribsp
permit
number
serum
sampl
collect
pig
aliquot
store
c
use
assay
elisa
prrsv
antibodi
perform
use
commerci
kit
bionot
inc
hwaseong
korea
accord
manufactur
instruct
optic
densiti
measur
nm
use
multiskan
plu
micropl
reader
labsystem
vantaa
finland
presenc
absenc
prrsv
antibodi
determin
calcul
sampl
posit
sp
ratio
sampl
consid
posit
prrsv
antibodi
sp
ratio
prrsv
vn
antibodi
titer
serum
sampl
collect
dpfv
analyz
indirect
immunofluoresc
assay
ifa
previous
describ
christopherhen
et
al
briefli
sampl
subject
uvtreat
min
inactiv
prrsv
subject
heat
inactiv
c
min
inactiv
complement
function
twofold
dilut
test
sampl
prepar
serum
free
dmem
mlwell
incub
ml
prrsv
tcid
per
well
h
c
subsequ
ml
suspens
transfer
microtit
plate
contain
confluent
monolay
cell
incub
h
c
mlwell
dmem
contain
fetal
bovin
serum
ad
well
incub
h
c
co
incub
content
well
remov
plate
cell
monolay
fix
aceton
water
min
plate
allow
dri
fumehood
min
cell
rehydr
mlwell
pb
min
cpe
plate
meant
viru
titrat
see
paragraph
vn
titer
examin
treatment
mlwell
mous
antipprsv
nucleocapsid
protein
specif
mab
follow
conjug
antimous
igg
h
l
secondari
antibodi
treatment
plate
incub
c
h
wash
time
treatment
observ
invert
fluoresc
microscop
mount
cell
monolay
glycerolpb
ratio
mlwell
vn
antibodi
titer
determin
reciproc
dilut
ratio
sampl
inhibit
prrsvinduc
immunofluoresc
observ
rectal
temperatur
measur
daili
day
postchalleng
dpc
threshold
fever
defin
c
respiratori
disord
score
normal
mild
dyspnea
andor
tachypnea
anim
stress
handl
mild
dyspnea
andor
tachypnea
rest
moder
dyspnea
andor
tachypnea
stress
moder
dyspnea
andor
tachypnea
rest
sever
dyspnea
andor
tachypnea
stress
sever
tachypnea
andor
dyspnea
rest
necropsi
lung
excis
macroscop
lung
lesion
score
estim
percentag
lung
affect
pneumonia
describ
halbur
et
al
one
gram
lung
tissu
collect
pig
ml
conic
tube
contain
ml
dmem
minc
homogen
use
ika
ultra
turrax
high
speed
homogen
coleparm
il
usa
one
min
ice
clarifi
supernat
collect
centrifug
min
aliquot
store
c
assay
cell
seed
onto
plate
h
infect
prrsv
supernat
serial
dilut
ml
dilut
plate
six
replic
well
cell
cultur
media
without
prrsv
use
control
cell
incub
c
h
co
incub
fix
immunostain
describ
prrsv
vn
titer
assay
titer
calcul
describ
previous
reed
muench
express
tcid
ml
prrsv
rna
extract
serum
sampl
lung
homogen
use
magmax
tm
viru
isol
kit
ambion
appli
biosystem
carlsbad
california
usa
per
manufactur
instruct
realtim
rtpcr
perform
use
ezprrsv
tm
mpx
assay
tetracor
rockvil
md
usa
cover
two
target
region
prrsv
type
type
gene
use
specif
primer
probe
assay
use
report
dye
detect
type
type
prrsv
altern
report
dye
use
detect
extractioninhibit
control
reaction
volum
per
well
includ
ml
ezprrsv
tm
mpx
reagent
includ
buffer
primer
probe
ml
enzym
blend
ml
extract
serum
sampl
pcr
run
includ
two
posit
control
type
type
virus
one
neg
amplif
control
neg
posit
control
per
well
contain
ml
ezprrsv
tm
mpx
reagent
ml
enzym
blend
ml
inhibit
control
ml
posit
ml
type
prrsv
neg
control
te
buffer
plate
briefli
mix
shake
vortex
mixer
centrifug
load
thermal
cycler
fast
realtim
pcr
system
appli
biosystem
foster
citi
ca
usa
thermal
cycl
condit
follow
one
cycl
c
min
one
cycl
c
min
cycl
c
c
sampl
c
valu
either
genotyp
prrsv
consid
posit
quantif
sampl
express
term
number
rna
copi
per
ml
serum
copi
per
gram
lung
tissu
estim
base
linear
extrapol
cycl
threshold
valu
standard
curv
gener
serial
dilut
known
amount
vitro
transcript
rna
product
copi
per
ml
data
express
mean
ae
standard
error
mean
sem
valu
pig
group
differ
bodi
temperatur
lung
patholog
score
humor
respons
viremia
group
assess
oneway
anova
follow
tukey
multipl
comparison
test
pvalu
consid
signific
statist
analysi
perform
use
graphpad
prism
softwar
version
graphpad
softwar
inc
san
diego
ca
usa
anim
remain
good
health
vaccin
kvadj
ckvadj
vaccin
prior
viral
challeng
local
system
vaccin
side
effect
absent
preand
postchalleng
none
experiment
pig
die
entir
studi
period
bodi
temperatur
anim
everi
group
fluctuat
within
normal
physiolog
rang
vaccin
statist
signific
data
shown
pig
challeng
bodi
temperatur
dkvadjvaccin
pig
group
remain
within
normal
rang
c
entir
studi
period
day
bodi
temperatur
anim
mockvaccin
control
ckvadjvaccin
pig
group
increas
c
day
day
postchalleng
respect
fig
signific
differ
mean
bodi
temperatur
mockvaccin
ckvadjvaccin
dkv
adjvaccin
pig
follow
viral
challeng
magnitud
increas
bodi
temperatur
correl
sever
clinic
diseas
ie
lower
bodi
temperatur
lower
overal
sever
clinic
diseas
sever
respiratori
disord
observ
challeng
dpc
respect
significantli
higher
respiratori
diseas
score
mockvaccin
ckvadjvaccin
anim
kvadjvaccin
pig
fig
bionot
elisa
demonstr
pig
seroneg
prrsv
dpfv
remain
low
dpfv
fig
anim
dkvadjand
ckvadjvaccin
group
becam
prrsv
seroposit
follow
dpfv
respect
fig
result
indic
dkvadj
vaccin
induc
greater
prrsv
specif
antibodi
product
commerci
ckvadjvaccin
pig
ckvadjvaccin
pig
becam
seroposit
dpc
fig
dpc
ckvadj
vaccin
group
show
significantli
higher
sp
ratio
compar
control
group
p
dpc
sp
ratio
kvadjvaccin
group
significantli
higher
ckv
adjvaccin
group
p
fig
signific
differ
sp
ratio
ckvadjvaccin
mockvaccin
pig
group
dpc
fig
addit
antibodi
titer
control
group
remain
neg
fig
serum
prr
vn
antibodi
titer
pig
analyz
standard
serum
neutral
assay
result
show
neither
dkvadj
ckvadj
vaccin
induc
vn
antibodi
type
type
first
second
vaccin
dkvadjvaccin
pig
vn
titer
detect
dpfv
fig
vn
titer
kvadjvaccin
group
significantli
higher
compar
ckvadjvaccin
pig
dpc
p
p
fig
rapid
vn
antibodi
respons
lkz
viru
observ
dkvadj
vaccin
pig
group
indic
vaccin
induc
better
protect
memori
immun
respons
assess
broad
vn
antibodi
activ
use
heterolog
prrsv
strain
type
vn
assay
detect
vn
titer
dpfv
pig
group
vaccin
dkvadj
fig
vn
titer
anim
significantli
higher
ckvadjvaccin
pig
group
dpc
p
p
fig
vn
titer
challeng
viru
strain
pig
group
vaccin
dkvadj
challeng
strain
similar
group
anim
challeng
homolog
viru
strain
indic
experiment
pig
receiv
prrsv
vaccin
strain
follow
heterolog
strain
challeng
gener
antibodi
broader
neutral
spectrum
signific
differ
macroscop
lung
lesion
score
observ
pig
group
necropsi
dpc
similar
trend
bodi
temperatur
less
clinicallyaffect
dkvadjvaccin
pig
significantli
fewer
lung
lesion
score
p
compar
sever
clinicallyaffect
mockvaccin
ckvadjvaccin
pig
fig
mockvaccin
ckvadjvaccin
pig
challeng
prrsv
gross
lung
lesion
cranial
middl
accessori
lobe
result
failur
lung
collaps
necropsi
lung
parenchyma
remain
firm
rubberi
obviou
lung
lesion
observ
dkvadjvaccin
pig
group
indic
vaccineadjuv
formul
enabl
pig
toler
challeng
type
type
prrsv
prrsv
rna
copi
number
lung
necropsi
dpc
measur
use
commerci
quantit
pcr
qpcr
kit
pig
group
immun
dkvadj
prrsv
rna
copi
undetect
anim
rna
copi
per
gram
lung
tissu
viral
load
mockvaccin
c
kvadjvaccin
pig
group
three
log
prrsv
threshold
detect
limit
howev
viral
load
group
significantli
differ
fig
serum
sampl
collect
dpfv
neg
prrsv
type
rna
copi
data
shown
viremia
challeng
assess
qpcr
viral
titer
cell
fig
prrsv
rna
could
detect
serum
sampl
obtain
pig
vaccin
viral
rna
copi
number
lung
homogen
quantifi
qrtpcr
limit
detect
rna
copiesml
data
shown
mean
ae
sem
viral
rna
copi
number
pig
group
p
analyz
twoway
anova
follow
tukey
multipl
comparison
test
kvadj
time
point
throughout
period
postchalleng
except
group
pig
observ
copi
dpc
follow
challeng
type
viral
strain
contrastingli
serum
collect
pig
vaccin
mock
ckv
adj
viremia
viral
copi
number
copi
fig
serum
sampl
also
analyz
viru
titrat
use
cell
fig
prrsv
detect
serum
pig
group
collect
dpfv
confirm
viru
properli
inactiv
data
shown
mockvaccin
pig
group
challeng
lkz
exhibit
highest
mean
viral
titer
log
tcid
ml
dpc
serum
sampl
respect
anim
vaccin
ckvadj
remain
virem
dpc
contrast
dkvadj
vaccin
pig
show
viremia
dpc
rtpcr
viral
isol
method
fig
inactiv
kill
mlv
prrsv
vaccin
commerci
avail
licens
use
mani
countri
control
reproduct
respiratori
form
prr
murtaugh
genzow
howev
vaccin
type
possess
strength
limit
due
safeti
issu
inactiv
vaccin
prefer
attenu
vaccin
howev
efficaci
current
inactiv
prrsv
vaccin
question
renukaradhya
et
al
scortti
et
al
vanhe
et
al
zuckermann
et
al
inactiv
prrsv
vaccin
field
situat
show
elicit
protect
immun
respons
certain
condit
depend
strain
infect
field
viru
employ
control
inactiv
procedur
use
suitabl
adjuv
inactiv
prrsv
vaccin
could
develop
systemat
induc
prrsv
specif
vn
antibodi
respons
two
vaccin
piglet
nilubol
et
al
serum
vn
antibodi
identifi
key
compon
protect
immun
prrsv
infect
osorio
et
al
research
previous
show
inactiv
vaccin
could
induc
vn
antibodi
result
strong
partial
virolog
protect
challeng
pig
misinzo
et
al
renukaradhya
et
al
experi
passiv
transfer
vn
antibodi
pig
prior
prrsv
infect
show
vn
antibodi
could
fulli
protect
pig
viremia
reproduct
failur
lopez
osorio
osorio
et
al
howev
other
observ
low
moder
degre
protect
heterolog
strain
viru
pig
immun
inactiv
prrsv
vaccin
labarqu
et
al
lager
et
al
intranas
deliveri
poli
lacticcoglycol
acid
nanoparticleentrap
uvkil
prrsv
vaccin
adjuv
solubl
mycobacterium
tuberculosi
deriv
wholecel
lysat
show
induct
crossprotect
immun
respons
pig
binjawadagi
et
al
binjawadagi
et
al
present
gener
accept
need
new
safe
vaccin
protect
homolog
heterologousheterogen
prrsv
infect
studi
object
assess
efficaci
candid
beiinactiv
prrsv
vaccin
dkvadj
contain
recent
isol
prrsv
field
strain
kazakhstan
homolog
type
heterogen
type
viral
challeng
commerci
kill
prrsv
vaccin
ckvadj
strain
type
select
refer
vaccin
use
immun
pig
prr
pig
farm
kazakhstan
efficaci
vaccin
candid
assess
evalu
abil
reduc
viremia
prevent
clinic
diseas
includ
lung
lesion
vaccin
pig
challeng
homolog
heterogen
prrsv
elisa
antibodi
analysi
demonstr
commerci
vaccin
induc
prrsvspecif
antibodi
howev
vaccin
pig
becam
seroposit
prior
challeng
challeng
day
ckvadj
vaccin
pig
becam
seroposit
howev
observ
vn
titer
serum
prechalleng
slightli
elev
neutral
antibodi
respons
detect
postchalleng
c
kvadjvaccin
pig
result
consist
publish
studi
scortti
et
al
zuckermann
et
al
wherein
vaccin
inactiv
prrsv
candid
vaccin
slightli
improv
vn
antibodi
respons
postchalleng
moreov
compar
mockvaccin
pig
ckvadj
vaccin
anim
becam
ill
postchalleng
manifest
characterist
clinic
sign
prr
sever
respiratori
disord
high
score
simultan
detect
viremia
notic
macroscop
lung
lesion
observ
necropsi
mockand
ckvadjvaccin
pig
challeng
type
type
data
indic
mean
prrsv
ae
sem
rna
copi
number
pig
group
data
b
express
geometr
mean
ae
sem
log
tcid
ml
pig
group
serum
sampl
pig
collect
dpc
dpfa
challeng
prrsv
limit
detect
assay
kit
rna
copi
per
ml
limit
detect
viru
titrat
assay
tcid
ml
viru
detect
high
challeng
viral
rna
copi
number
lung
thu
conclud
commerci
ckvadj
vaccin
pig
protect
clinic
diseas
viremia
lung
lesion
field
variant
kazakh
strain
prrsv
result
line
earlier
studi
vaccin
prr
field
provid
variabl
degre
protect
report
clinic
outbreak
prr
vaccin
pig
led
doubt
efficaci
current
commerci
prrsv
vaccin
geldhof
et
al
thanawongnuwech
suradhat
contrast
elisa
result
demonstr
dkvadjvaccin
pig
produc
prrsvspecif
antibodi
rapidli
ckvadj
seroposit
third
immun
vn
antibodi
detect
anim
vaccin
dkvadj
prior
challeng
albeit
low
level
interestingli
vn
titer
reduc
challeng
pig
vaccin
dkvadj
anim
consist
high
vn
titer
homolog
heterogen
prrsv
data
agreement
earlier
studi
show
high
vn
titer
requir
time
challeng
offer
full
protect
high
dose
viru
use
infect
anim
geldhof
et
al
detect
level
replic
prrsv
absent
postchalleng
dkvadj
vaccin
pig
could
attribut
earli
appear
prechalleng
vn
antibodi
target
put
neutral
epitop
prrsv
protein
yang
et
al
need
investig
inactiv
vaccin
predominantli
elicit
respons
spellberg
edward
exclud
possibl
respons
dkvadjvaccin
pig
also
requir
research
type
type
prrsv
strain
challeng
pig
vaccin
dkvadj
observ
strong
associ
induct
virusspecif
neutral
antibodi
respons
absenc
viremia
lung
lesion
clinic
diseas
indic
vn
antibodi
may
contribut
significantli
crossprotect
similar
result
also
observ
previou
studi
candid
vaccin
challeng
heterolog
type
strain
viru
find
demonstr
candid
kill
prrsv
vaccin
safeti
profil
efficaci
administ
three
time
day
largewhit
breed
pig
age
month
result
studi
interest
candid
kill
prrsv
vaccin
provid
strong
heterogen
protect
even
modifi
live
prrsv
vaccin
shown
ineffect
intergenotyp
viru
provid
incomplet
protect
reinfect
heterolog
virus
botner
et
al
kimman
et
al
martelli
et
al
renukaradhya
et
al
b
reason
beyond
better
protect
respons
candid
vaccin
could
attribut
vaccin
pig
three
time
montanid
tm
seppic
adjuv
compar
other
wherein
mani
vaccin
trial
kill
subunit
prrsv
vaccin
vaccin
twice
use
rel
weaker
adjuv
montanid
adjuv
renukaradhya
et
al
furthermor
moment
due
lack
genom
sequenc
data
vaccin
challeng
virus
difficult
draw
meaning
conclus
interest
result
studi
although
candid
beiinactiv
prrsv
vaccin
adjuv
montanid
tm
gel
st
provid
protect
homolog
type
heterogen
type
strain
viru
confirm
vaccin
formul
would
crossprotect
heterogen
heterolog
field
strain
virus
need
vaccin
trial
due
lack
sequenc
data
vaccin
challeng
virus
use
studi
like
though
commerci
vaccin
viru
challeng
viru
strain
type
virus
level
genet
variabl
known
howev
knowledg
first
report
demonstr
inactiv
prrsv
vaccin
could
also
provid
crossprotect
respons
differ
viral
genotyp
pig
offer
new
perspect
develop
effect
safe
prrsv
vaccin
author
declar
potenti
actual
conflict
interest
